Trials / Unknown
UnknownNCT05124028
A Study of Orelabrutinib in Patients With ITP
A Study of Orelabrutinib in Patients With Primary Immune Thrombocytopenia (ITP)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).
Detailed description
The investigators are undertaking a prospective trial of 10 adults with ITP in China. Orelabrutinib is administered as 50 mg po. qd for 6 weeks. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib | 50mg po qd 6 weeks |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-03-01
- Completion
- 2022-06-01
- First posted
- 2021-11-17
- Last updated
- 2021-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05124028. Inclusion in this directory is not an endorsement.